Drug Safety

, Volume 13, Issue 2, pp 81–93 | Cite as

Health Risks of Herbal Remedies

  • Peter A. G. M. De Smet


Herbal remedies can result in indirect health risks when they delay or replace a more effective form of conventional treatment or when they compromise the efficacy of conventional medicines. Herbal remedies can also be associated with direct health risks. Long-standing traditional experience may tell much about striking and predictable symptoms of acute toxicity but it is a less reliable tool for the detection of reactions which are inconspicuous, develop gradually or have a prolonged latency period, or which occur uncommonly. Another reason why safety claims cannot always be based on traditional empiricism is that not all herbal remedies are firmly rooted in traditional medicine.

The risk of a herbal remedy producing an adverse reaction depends not only on the remedy and its dosage but also on consumer-related parameters, such as age, genetics, concomitant diseases and concurrent use of other drugs. Another important determinant of the toxicity of herbal remedies is their quality.

What is already known about the risks of herbal remedies must be systematically collected, disseminated and acted upon. What is yet unknown must be found out by herbal postmarketing surveillance and experimental research.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    De Smet PAGM. Legislatory outlook on the safety of herbal remedies. In: De Smet PAGM, Hänsel R, Keller, et al., editors. Adverse effects of herbal drugs. Vol 2. Heidelberg: Springer-Verlag, 1993: 1–90CrossRefGoogle Scholar
  2. 2.
    De Smet PAGM, Stricker BHCh, Nijman JJ. Indirecte risico’s van alternatieve middelen. Een oproep tot het rapporteren van concrete gevallen. Med Contact 1994; 49: 1593–4Google Scholar
  3. 3.
    Verrept H. Marokkaaanse migranten en hun geneesmiddelen. Med Antropol 1992; 4: 184–98Google Scholar
  4. 4.
    Verrept H, Schillemans L. Ziektegedrag van Marokkaaanse migranten met vakantie in Marokko. Ned Tijdschr Geneeskd 1994; 138: 337–9PubMedGoogle Scholar
  5. 5.
    Dandekar UP, Chandra RS, Dalvi SS, et al. Analysis of a clinically important interaction between phenytoin and Shankhapushpi, an Ayurvedic preparation. J Ethnopharmacol 1992; 35: 285–8PubMedCrossRefGoogle Scholar
  6. 6.
    Shima K, Tanaka A, Ikegami H, et al. Effect of dietary fiber, glucomannan, on absorption of sulfonylurea in man. Horm Metab Res 1983; 15: 1–3PubMedCrossRefGoogle Scholar
  7. 7.
    Huupponen R, Seppälä P, Iisalo E. Effect of guar gum, a fibre preparation, on digoxin and penicillin absorption in man. Eur J Clin Pharmacol 1984; 26: 279–81PubMedCrossRefGoogle Scholar
  8. 8.
    Gin H, Orgerie MB, Aubertin J. The influence of guar gum on absorption of metformin from the gut in healthy volunteers. Horm Metab Res 1989; 21: 81–3PubMedCrossRefGoogle Scholar
  9. 9.
    Jaeger A, George C, Lambert H, et al. Les accidents immunoallergiques au cours des traitements par un veinotrope contenant des catéchines. Trois observations. Thérapie 1980; 35: 733–41PubMedGoogle Scholar
  10. 10.
    Wälti M, Neftel KA, Jost R, et al. IgE- und IgG-Antikörpergegen Flavonoide nach Therapie mit flavonoidhaltigen Medikamenten. Schweiz Med Wochenschr 1986; 116: 98–103PubMedGoogle Scholar
  11. 11.
    Imbasciati E, De Cristofaro V, Scherini A, et al. Acute renal failure due to (+)-cyanidanol-3-induced hemolytic anemia. Nephron 1987; 46: 323PubMedCrossRefGoogle Scholar
  12. 12.
    Gandolfo GM, Girelli G, Conti L, et al. Hemolytic anemia and thrombocytopenia induced by cyanidanol. Acta Haematol 1992; 88: 96–9PubMedCrossRefGoogle Scholar
  13. 13.
    Lin JL, Ho YS. Flavonoid-induced acute nephropathy. Am J Kidney Dis 1994; 23: 433–40PubMedGoogle Scholar
  14. 14.
    Maechel H. Diarrhée chronique secondaire au Cirkan. Gastroenterol Clin Biol 1992; 16: 373PubMedGoogle Scholar
  15. 15.
    Thomas-Anterion C, Guy Cl, Vial F, et al. Diarrhées chroniques inexpliquées, à propos de quatre nouveaux cas sous Cyclo 3 fort® et revue de la littérature. Rev Med Interne 1993; 14: 215–7PubMedCrossRefGoogle Scholar
  16. 16.
    Beaugerie L, Luboinski J, Brousse N, et al. Drug induced lymphocytic colitis. Gut 1994; 35: 426–8PubMedCrossRefGoogle Scholar
  17. 17.
    Takegoshi K, Tohyama T, Okuda K, et al. A case of Venoplant-induced hepatic injury. Gastroenterol Jpn 1986; 21: 62–5PubMedGoogle Scholar
  18. 18.
    Jiménez Gómez R, Saldaña Garrido D, Martín Arias LH, et al. Somnolencia en el curso de un tratamiento con diosmina. Med Clin 1991; 97: 198–9Google Scholar
  19. 19.
    Hausen BM, Bruhn G, Tilsley DA. Contact allergy to Australian blackwood (Acacia melanoxylon R.Br.): isolation and identification of new hydroxyflavan sensitizers. Contact Dermatitis 1990; 23: 33–9PubMedCrossRefGoogle Scholar
  20. 20.
    Geier J, Fuchs T, Wahl R. Anaphylaktischer Schock durch einen Mariendistel-Extrakt bei Soforttyp-Allergie auf Kiwi. Allergologie 1989; 13: 387–8Google Scholar
  21. 21.
    Daniel PT, Holzschuh J, Berg PA. The pathogenesis of cianidanol-induced fever. Eur J Clin Pharmacol 1988; 34: 241–7PubMedCrossRefGoogle Scholar
  22. 22.
    Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992; 34: 377–95PubMedCrossRefGoogle Scholar
  23. 23.
    Lacomblez L, Bensimon G, Isnard F, et al. Effect of yohimbine on blood pressure in patients with depression and orthostatic hypotension induced by clomimpramine. Clin Pharmacol Ther 1989; 45: 241–51PubMedCrossRefGoogle Scholar
  24. 24.
    Landis E, Shore E. Yohimbine-induced bronchospasm. Chest 1989; 96: 1424PubMedCrossRefGoogle Scholar
  25. 25.
    Sandler B, Aronson P. Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome. Urology 1993; 41: 343–5PubMedCrossRefGoogle Scholar
  26. 26.
    Kommission E — Aufberereitungsmonographien. Dtsch Apoth Ztg 1993; 133: 2791–4Google Scholar
  27. 27.
    De Smet PAGM. Drugs used in non-orthodox medicine. In: Dukes MNG, editor. Side effects of drugs. 12th ed. Amsterdam: Elsevier, 1992: 1209–32Google Scholar
  28. 28.
    Shibata MA, Hirose M, Tanaka H, et al. Induction of renal cell tumors in rats and mice, and enhancement of hepatocellular tumor development in mice after long-term hydroquinone treatment. Jpn J Cancer Res 1991; 82: 1211–9PubMedCrossRefGoogle Scholar
  29. 29.
    Kari FW, Bucher J, Eustis SL, et al. Toxicity and carcinogenicity of hydroquinone in F344/N rats and B6C3F1 mice. Food Chem Toxicol 1992; 30: 737–47PubMedCrossRefGoogle Scholar
  30. 30.
    Frohne D. Untersuchungen zur Frage der harndesinfizierenden Wirkungen von Bärentraubenblatt-Extrakten. Planta Med 1970; 18: 1–25PubMedCrossRefGoogle Scholar
  31. 31.
    Divicenzo GD, Hamilton ML, Reynolds RC, et al. Metabolic fate and disposition of (14C)hydroquinone given orally to Sprague-Dawley rats. Toxicology 1984; 33: 9–18CrossRefGoogle Scholar
  32. 32.
    Oso BA. Mushrooms and the Yoruba people of Nigeria. Mycologia 1975; 67: 311–9PubMedCrossRefGoogle Scholar
  33. 33.
    De Smet PAGM. Ethnopharmacological art in perspective: enema scenes in black African sculpture. Int Pharm J 1992; 6: 197–202, 239-44Google Scholar
  34. 34.
    De Smet PAGM. An introduction to herbal pharmacoepidemiology. J Ethnopharmacol 1993; 38: 197–208PubMedCrossRefGoogle Scholar
  35. 35.
    De Smet PAGM, Vulto AG. Drugs used in non-orthodox medicine. In: Dukes MNG, editor. Side effects of drugs. Annual 11. Amsterdam: Elsevier, 1987: 422–31Google Scholar
  36. 36.
    Onrot J, Goldberg MR, Biaggioni I, et al. Oral yohimbine in human autonomic failure. Neurol 1987; 37: 215–20CrossRefGoogle Scholar
  37. 37.
    Price LH, Charney DS, Heninger GR. Three cases of manic symptoms following yohimbine administration. Am J Psychiatry 1984; 141: 1267–8PubMedGoogle Scholar
  38. 38.
    Ingram CG. Some pharmacologic actions of yohimbine and chlorpromazine in man. Clin Pharmacol Ther 1962; 3: 345–52Google Scholar
  39. 39.
    Carbo M, Segura J, De la Torre R, et al. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther 1989; 45: 234–40PubMedCrossRefGoogle Scholar
  40. 40.
    Harder S, Fuhr U, Staib AH, et al. Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations. Am J Med 1989; 87: 89S–91SPubMedCrossRefGoogle Scholar
  41. 41.
    Healy DP, Polk RE, Kanawati L, et al. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother 1989; 33: 474–8PubMedCrossRefGoogle Scholar
  42. 42.
    Mahr G, Soergel F, Granneman GR, et al. Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. Clin Pharmacokinet 1992; 22Suppl. 1: 90–7PubMedCrossRefGoogle Scholar
  43. 43.
    Schellens JH, Ghabrial H, van der Wart HH, et al. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans. Clin Pharmacol Ther 1991; 50: 520–8PubMedCrossRefGoogle Scholar
  44. 44.
    Gram LF, Debruyne D, Caillard V, et al. Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol 1989; 27: 272–5PubMedCrossRefGoogle Scholar
  45. 45.
    Gram LF, Brosen K, Danish University Antidepressant Group. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Br J Clin Pharmacol 1993; 35: 649–52PubMedCrossRefGoogle Scholar
  46. 46.
    Galloway JH, Farmer K, Weeks GR, et al. Potentially hazardous compound in a herbal slimming remedy. Lancet 1992; 340: 179PubMedCrossRefGoogle Scholar
  47. 47.
    Atal CK, Zutshi U, Bedi KL, et al. Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs. J Ethnopharmacol 1981; 4: 229–32PubMedCrossRefGoogle Scholar
  48. 48.
    Bano G, Raina RK, Zutshi U, et al. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol 1991; 41: 615–7PubMedCrossRefGoogle Scholar
  49. 49.
    Atal CK, Dubey RK, Singh J. Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. J Pharmacol Exp Ther 1985; 232: 258–62PubMedGoogle Scholar
  50. 50.
    Bhat BG, Chandrasekhara N. Interaction of piperine with rat liver microsomes. Toxicology 1987; 44: 91–8PubMedCrossRefGoogle Scholar
  51. 51.
    Bano G, Amla V, Raina RK, et al. The effect of piperine on pharmacokinetics of phenytoin in healthy volunteers. Planta Med 1987; 53: 568–9PubMedCrossRefGoogle Scholar
  52. 52.
    Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokinet 1994; 26: 91–8PubMedCrossRefGoogle Scholar
  53. 53.
    De Smet PAGM, Smeets OSNM. Potential risks of health food products containing yohimbe extracts. BMJ 1994; 309: 958PubMedCrossRefGoogle Scholar
  54. 54.
    Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 341: 387–91PubMedCrossRefGoogle Scholar
  55. 55.
    Vanhaelen M, Vanhaelen-Fastre R, But P, et al. Identification of aristolochic acid in Chinese herbs. Lancet 1994; 343: 174PubMedCrossRefGoogle Scholar
  56. 56.
    Quansheng C. Mutong. In: Chang H-M, But PP-H, editors. Pharmacology and applications of Chinese materia medica. Vol 1. Singapore: World Scientific Publishing, 1986: 195–8Google Scholar
  57. 57.
    De Smet PAGM. Aristolochia species. In: De Smet PAGM, Keller K, Hänsel R, et al., editors. Adverse effects of herbal drugs. Vol 1. Heidelberg: Springer-Verlag, 1992: 79–89CrossRefGoogle Scholar
  58. 58.
    But PP. Herbal poisoning caused by adulterants or erroneous substitutes. J R Trop Med Hyg 1994; 97: 371–4Google Scholar
  59. 59.
    De Smet PAGM, Elferink F, Verpoorte R. Linksdraaiend tetrahydropalmatine in Chinese tablet. Ned T Geneesk 1989; 133: 308PubMedGoogle Scholar
  60. 60.
    Quansheng C. Yanhusuo. In: Chang H-M, But PP-H, editors. Pharmacology and applications of Chinese materia medica. Vol 1. Singapore: World Scientific Publishing, 1986: 515–24Google Scholar
  61. 61.
    Horowitz RS, Gomez H, Moore LL, et al. Jin Bu Huan toxicity in children — Colorado 1993. MMWR 1993; 42: 633–6Google Scholar
  62. 62.
    Woolf GM, Petrovic LM, Rojter SE, et al. Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. Ann Intern Med 1994; 121: 729–35PubMedGoogle Scholar
  63. 63.
    De Smet PAGM. Scutellaria species. In: De Smet PAGM, Keller K, Hänsel R, et al., editors. Adverse effects of herbal drugs. Vol 2. Heidelberg: Springer-Verlag, 1993: 289–96, 317CrossRefGoogle Scholar
  64. 64.
    De Smet PAGM. Toxicological outlook on the quality assurance of herbal remedies. In: De Smet PAGM, Keller K, Hänsel R, et al., editors. Adverse effects of herbal drugs. Vol 1. Heidelberg: Springer-Verlag, 1992: 1–72CrossRefGoogle Scholar
  65. 65.
    De Smet PAGM, Elferink F. Te veel lood in Chinese kruidenpillen. Pharm Weekbl 1990; 125: 169Google Scholar
  66. 66.
    McElvaine MD, Harder EM, Johnson L, et al. Lead poisoning from the use of Indian folk medicines. JAMA 1990; 264: 2212–3PubMedCrossRefGoogle Scholar
  67. 67.
    Mitchell-Heggs CAW, Conway M, Cassar J. Herbal medicine as a cause of combined lead and arsenic poisoning. Hum Exp Toxicol 1990; 9: 195–6PubMedCrossRefGoogle Scholar
  68. 68.
    Dolan G, Jones AP, Blumsohn A, et al. Lead poisoning due to Asian ethnic treatment for impotence. J R Soc Med 1991; 84: 630–1PubMedGoogle Scholar
  69. 69.
    Goldman JA, Myerson G. Chinese herbal medicine: camouflaged prescription antiinflammatory drugs, corticosteroids, and lead. Arthritis Rheum 1991; 34: 1207PubMedCrossRefGoogle Scholar
  70. 70.
    Saryan LA. Surreptitious lead exposure from an Asian Indian medication. J Anal Toxicol 1991; 15: 336–8PubMedGoogle Scholar
  71. 71.
    Smitherman J, Harber P. A case of mistaken identity: herbal medicine as a cause of lead toxicity. Am J Ind Med 1991; 20: 795–8PubMedCrossRefGoogle Scholar
  72. 72.
    Dunbabin DW, Tallis GA, Popplewell PY, et al. Lead poisoning from Indian herbal medicine (Ayurveda). Med J Aust 1992; 157: 835–6PubMedGoogle Scholar
  73. 73.
    Kang-Yum E, Oransky SH. Chinese patent medicine as a potential source of mercury poisoning. Vet Hum Toxicol 1992; 34: 235–8PubMedGoogle Scholar
  74. 74.
    Schaumburg HH, Berger A. Alopecia and sensory polyneuropathy from thallium in a Chinese herbal medication. JAMA 1992; 268: 3430–1PubMedCrossRefGoogle Scholar
  75. 75.
    Kew J, Morris C, Aihie A, et al. Arsenic and mercury intoxication due to Indian ethnic remedies. BMJ 1993; 306: 506–7PubMedCrossRefGoogle Scholar
  76. 76.
    Keen RW, Deacon AC, Delves HT, et al. Indian herbal remedies for diabetes as a cause of lead poisoning. Postgrad Med J 1994; 70: 113–4PubMedCrossRefGoogle Scholar
  77. 77.
    Markowitz SB, Nunez CM, Klitzman S, et al. Lead poisoning due to Hai Ge Fen. The porphyrin content of individual erythrocytes. JAMA 1994; 271: 932–4PubMedCrossRefGoogle Scholar
  78. 78.
    Perharic L, Shaw D, Colbridge M, et al. Toxicological problems resulting from exposure to traditional remedies and food supplements. Drug Saf 1994; 11: 284–94PubMedCrossRefGoogle Scholar
  79. 79.
    Sheerin NS, Monk PN, Aslam M, et al. Simultaneous exposure to lead, arsenic and mercury from Indian ethnic remedies. Br J Clin Pract 1994; 48: 332–3PubMedGoogle Scholar
  80. 80.
    De Smet PAGM, Elferink F, Kerremans ALM, et al. Dexamethason in oosterse Cow’s Head Brand Tung Shueh pillen. Pharm Weekbl 1990; 125: 414–5Google Scholar
  81. 81.
    DuPont RL, Bogema SC. Benzodiazepines in a health-catalog product. JAMA 1990; 264: 695PubMedCrossRefGoogle Scholar
  82. 82.
    Barnes AR, Paul CJ, Secrett PC. Adulteration of an Asian alternative medicine. Pharm J 1991; 247: 650Google Scholar
  83. 83.
    Floren AE, Fitter W. Contamination of urine with diazepam and mefenamic acid from an Oriental remedy. J Occup Med 1991; 33: 1168–9PubMedCrossRefGoogle Scholar
  84. 84.
    Joseph AM, Biggs T, Garr M, et al. Stealth steroids. N Engl J Med 1991; 324: 62PubMedGoogle Scholar
  85. 85.
    Karunanithy R, Sumita KP. Undeclared drugs in traditional Chinese antirheumatoid medicine. Int J Pharm Pract 1991; 1: 117–9CrossRefGoogle Scholar
  86. 86.
    Segasothy M, Samad S. Illicit herbal preparation containing phenylbutazone causing analgesic nephropathy. Nephron 1991; 59: 166–7PubMedCrossRefGoogle Scholar
  87. 87.
    Diamond JR, Pallone TL. Acute interstitial nephritis following use of Tung Shueh pills. Am J Kidney Dis 1994; 24: 219–21PubMedGoogle Scholar
  88. 88.
    De Smet PAGM, Smeets OSNM. Dexamethason in Oosterse ‘Gentian Rheumatism’ capsules. Pharm Weekbl 1994; 129: 30Google Scholar
  89. 89.
    Graham-Brown RAC, Bourke JF, Bumphrey G. Chinese herbal remedies may contain steroids. BMJ 1994; 308: 473PubMedCrossRefGoogle Scholar
  90. 90.
    Hughes JR, Higgins EM, Pembroke AC. Oral dexamethasone masquerading as a Chinese herbal remedy. Br J Dermatol 1994; 130: 261PubMedCrossRefGoogle Scholar
  91. 91.
    Van der Stricht BI, Parvais OE, Vanhaelen-Fastré RJ, et al. Remedies may contain cocktail of active drugs. BMJ 1994; 308: 1162CrossRefGoogle Scholar
  92. 92.
    Abt AB, Oh JY, Huntington RA, et al. Chinese herbal medicine induced acute renal failure. Arch Int Med 1995; 155: 211–2CrossRefGoogle Scholar
  93. 93.
    Osol A, Farrar GE. The Dispensatory of the United States of America. 25th ed. Philadelphia: J.B. iLippincott Company, 1955Google Scholar
  94. 94.
    Lewin L. Gifte und Vergiftungen. Lehrbuch der Toxikologie. Fünfte unveränderte Ausgabe. Ulm/Donau: Karl F. Haug Verlag, 1962Google Scholar
  95. 95.
    Kingsbury JM. Poisonous plants of the United States and Canada. Englewood Cliffs: Prentice-Hall Inc, 1964Google Scholar
  96. 96.
    Gessner O, Orzechowski G. Gift- und Arzneipflanzen von Mitteleuropa. 3. Auflage. Heidelberg: Carl Winter Universitäts-verlag, 1974Google Scholar
  97. 97.
    Madaus G. Lehrbuch der biologischen Heilmittel. Band I–III. Hildesheim: Georg Olms Verlag, 1979Google Scholar
  98. 98.
    Mitchell J, Rook A. Botanical dermatology. Plants and plant products injurious to the skin. Vancouver: Greengrass, 1979Google Scholar
  99. 99.
    Moeschlin S. Klinik und Therapie der Vergiftungen. 7. Auflage. Stuttgart: Georg Thieme Verlag, 1986Google Scholar
  100. 100.
    Chang H-M, But PP-H, editors. Pharmacology and applications of Chinese materia medica. Vol 1. Singapore: World Scientific Publishing, 1986Google Scholar
  101. 101.
    Chang H-M, But PP-H, editors. Pharmacology and applications of Chinese materia medica. Vol 2. Singapore: World Scientific Publishing, 1987Google Scholar
  102. 102.
    Frohne D, Pfänder HJ. Giftpflanzen. 3rd ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1987Google Scholar
  103. 103.
    Der Marderosian A, Liberti LE. Natural product medicine. A scientific guide to foods, drugs, cosmetics. Philadelphia: George F. Stickley Company, 1988Google Scholar
  104. 104.
    De Smet PAGM, Keller K, Hänsel R, et al. Adverse effects of herbal drugs. Vol 1. Heidelberg: Springer-Verlag, 1992CrossRefGoogle Scholar
  105. 105.
    Hänsel R, Keller K, Rimpler H, et al. Hagers Handbuch der Pharmazeutischen Praxis. 5th ed. Vierter Band: Drogen A–D. Berlin: Springer-Verlag, 1992Google Scholar
  106. 106.
    Stricker BHCh, De Smet PAGM. Individual agents: herbal and other non-orthodox agents. In: Stricker BHCh, editor. Drug-induced hepatic injury. 2nd ed. Amsterdam: Elsevier Science Publishers, 1992: 525–38Google Scholar
  107. 107.
    Tang W, Eisenbrand G. Chinese drugs of plant origin. Chemistry, pharmacology, and use in traditional and modern medicine. Heidelberg: Springer-Verlag, 1992Google Scholar
  108. 108.
    De Smet PAGM, Keller K, Hänsel R, et al. Adverse effects of herbal drugs. Vol 2. Heidelberg: Springer-Verlag, 1993CrossRefGoogle Scholar
  109. 109.
    Hänsel R, Keller K, Rimpler H, et al. Hagers Handbuch der Pharmazeutischen Praxis. 5th ed. Fünfter Band: Drogen E–O. Berlin: Springer-Verlag, 1993Google Scholar
  110. 110.
    Tyler VE. The new honest herbal. A sensible guide to the use of herbs and related remedies. 3rd ed. Binghamton: Pharmaceutical Products Press, 1993Google Scholar
  111. 111.
    Bisset NG, Wichtl M, editors. Herbal drugs and phytopharmaceuticals. A handbook for practice on a scientific basis. Stuttgart: Medpharm Scientific Publishers, 1994Google Scholar
  112. 112.
    Hänsel R, Keller K, Rimpler H, et al. Hagers Handbuch der Pharmazeutischen Praxis. 5th ed. Fünfter Band: Drogen P-Z. Berlin: Springer-Verlag, 1994Google Scholar
  113. 113.
    Roth L, Daunderer M, Kormann K. Giftpflanzen — Pflanzengifte: Wirkung, Vorkommen, Wirkung, Therapie; allergische und phototoxische Reaktionen. 4. Auflage, Landsberg: Ecomed, 1994Google Scholar
  114. 114.
    Teuscher E, Lindequist U. Biogene Gifte. Biologie — Chemie-Pharmakologie. 2. Auflage. Stuttgart: Gustav Fischer, 1994Google Scholar
  115. 115.
    De Smet PAGM, D’Arcy PF. Drug interactions with herbal and other non-orthodox drugs. In: D’ Arcy PF, McElnay JC, Welling PG, editors. Mechanisms of drug interactions. Heidelberg: Springer Verlag. In pressGoogle Scholar
  116. 116.
    De Smet PAGM, Keller K, Hänsel R, et al. Adverse effects of herbal drugs. Vol 3. Heidelberg: Springer-Verlag. In pressGoogle Scholar
  117. 117.
    Kao W-F, Hung D-Z, Lin K-P, et al. Podophyllotoxin intoxication: toxic effect of Bajiaolian in herbal therapeutics. Hum Exp Toxicol 1992; 11: 480–7PubMedCrossRefGoogle Scholar
  118. 118.
    Deji D, Qingtian Z. Shancigu. In: Chang H-M, But PP-H, editors. Pharmacology and applications of Chinese materia medica. Vol 1. Singapore: World Scientific Publishing Co, 1986: 117–23Google Scholar
  119. 119.
    Songbai Y. Zangqie. In: Chang H-M, But PP-H, editors. Pharmacology and applications of Chinese materia medica. Vol 2. Singapore: World Scientific Publishing Co, 1987: 1250–5Google Scholar
  120. 120.
    Arzneimittelkommission der Deutschen Apotheker. Chinesisches Pflanzenpulver. Dtsch Apoth Ztg 1994; 134: 2212Google Scholar
  121. 121.
    Pourrat J, Montastruc JL, Lacombe JL, et al. Néphropathie associée des herbes chinoises 2 cas. Presse Med 1994; 23: 1669PubMedGoogle Scholar
  122. 122.
    Auriche M, Loupi E. Does proof of causality ever exist in pharmacovigilance? Drug Saf 1993; 9: 230–5PubMedCrossRefGoogle Scholar
  123. 123.
    De Smet PAGM. Should herbal medicine-like products be licensed as medicines. Special licensing seems the best way forward. BMJ 1995; 310: 1023–4PubMedCrossRefGoogle Scholar
  124. 124.
    Herbert V, Drivas G. Spirulina and vitamin B12. JAMA 1982; 248: 3096–7PubMedCrossRefGoogle Scholar
  125. 125.
    Herbert V. The 1986 Herman Award Lecture. Nutrition science as a continually unfolding story: the folate and vitamin B12 paradigm. Am J Clin Nutr 1987; 46: 387–402PubMedGoogle Scholar
  126. 126.
    Van den Berg H, Dagnelie PC, Van Staveren WA. Vitamin B12 and seaweed. Lancet 1988; 1: 242–3PubMedCrossRefGoogle Scholar
  127. 127.
    Dagnelie PC, Van Staveren WA, Van den Berg H. Vitamin B12 from algae appears not to be bioavailable. Am J Clin Nutr 1991; 53: 695–7, 988PubMedGoogle Scholar
  128. 128.
    Atherton DJ. Towards the safer use of traditional remedies. Greater awareness of toxicity is needed. BMJ 1994; 308: 673–4PubMedCrossRefGoogle Scholar
  129. 129.
    Smith T, editor. The British Medical Association family doctor — home adviser. The first practical guide to understanding your symptoms and recognising medical emergencies. 2nd ed. London: Dorling Kindersley, 1992: 154–5Google Scholar
  130. 130.
    Castot A, Larrey D. Hépatites observées au cours d’un traitement par un médicament ou une tisane contenant de la germandrée petit-chêne. Bilan des 26 cas rapportés aux Centres Régionaux de Pharmacovigilance. Gastroenterol Clin Biol 1992; 16: 916–22PubMedGoogle Scholar
  131. 131.
    Siegers C-P, Von Hertzberg-Lottin E, Otte M, et al. Anthranoid laxative abuse — a risk for colorectal cancer? Gut 1993; 34: 1099–101PubMedCrossRefGoogle Scholar
  132. 132.
    De Smet PAGM, Vulto AG. Drugs used in non-orthodox medicine. In: Dukes MNG, Beeley L, editors. Side effects of drugs. Annual 12. Amsterdam: Elsevier, 1988: 402–15Google Scholar
  133. 133.
    Westendorf J, Marquardt H, Poginsky B, et al. Genotoxicity of naturally occurring hydroxyanthraquinones. Mutat Res 1990; 240: 1–12PubMedCrossRefGoogle Scholar
  134. 134.
    Siegers C-P. Anthranoid laxatives and colorectal cancer. Trends Pharmacol Sci 1992; 13: 229–31PubMedCrossRefGoogle Scholar
  135. 135.
    Mori H, Sugie S, Niwa K, et al. Induction of intestinal tumours in rats given chrysazin. Br J Cancer 1985; 52: 781–3PubMedCrossRefGoogle Scholar
  136. 136.
    Mori H, Sugie S, Niwa K, et al. Carcinogenicity of chrysazin in large intestine and liver of mice. Jpn J Cancer Res 1986; 77: 871–6PubMedGoogle Scholar
  137. 137.
    Mori H, Yoshimi N, Iwata H, et al. Carcinogenicity of naturally occurring 1-hydroxyanthraquinone in rats: induction of large bowel, liver and stomach neoplasms. Carcinogenesis 1990; 11: 799–802PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Peter A. G. M. De Smet
    • 1
  1. 1.Drug Information CenterRoyal Dutch Association for the Advancement of PharmacyThe HagueThe Netherlands

Personalised recommendations